Untreated severe tricuspid regurgitation (TR) carries a poor prognosis. The authors report the 1-year outcomes of transcatheter edge-to-edge repair (TEER) with the TriClip system (Abbott Structural Heart) in patients with complex tricuspid valve anatomies.

4 天之前 · Taking into account the high rates of crossover from the treatment arm to the control arm and the non-blinded study design, the results highlight the long-term durability of tricuspid TEER with the TriClip device. The initial benefits—TR reduction, improved health status, and procedural safety—persisted through two years of follow-up.

3 天之前 · In the control arm, 63% of patients had moderate or less TR, which was primarily driven the patients who crossed over to TEER. The annualized HF hospitalization rates were 0.19 and 0.26 per patient-year in the device and control arms, respectively (joint frailty HR …

Background: The ValveClasp system is a novel transcatheter edge-to-edge repair (TEER) device with an arm-width-expandable clip that allows treatment of patients with only one clip more frequently. Objectives: This study aimed to evaluate the feasibility and safety of a novel TEER device in porcine models and patients.

2024年5月2日 · Cardiac surgeons and interventional cardiologists in China have completed the very first robot-assisted transcatheter edge-to-edge repair (TEER), sharing their initial findings in JACC: Cardiovascular Interventions.[1]

2024年9月12日 · Tricuspid transcatheter edge-to-edge repair (T-TEER) with the TriClip device (Abbott) continues to offer sustained benefits 3 years after the intervention in patients with symptomatic moderate or greater tricuspid regurgitation (TR), final results from the TRILUMINATE single-arm trial show.

2024年5月13日 · 经导管缘对缘修复（TEER）已成为治疗二尖瓣反流最主要、最广泛认可的方法。 由于二尖瓣反流机制与解剖结构错综复杂，相较于其他导管技术，TEER的操作复杂度较高，更需多学科团队的协作和规范化操作，以最大程度确保患者的安全并获得更优预后。 MitraClip是目前植入量最大的二尖瓣介入治疗器械，为进一步规范MitraClip TEER操作，本期特邀国际知名专家Gilbert Tang教授以step-by-step的形式全面展示MitraClip系统的规范化操作步骤及其中的操作 …

2 天之前 · Safety outcomes through 2 years were largely comparable between groups, barring a numerical excess in single leaflet device attachment with the assigned TEER arm (6.5% vs 3.9%).

Evaluation of the Efficacy and Limitations of the TRILUMINATE Pivotal Single-Arm Study of Tricuspid TEER Sign in, Subscribe, or Pay to View GET ACCESS. Editorial Comment. Nina C. Wunderlich; Nina C. Wunderlich. ∗Address for correspondence: Dr Nina C. Wunderlich, Asklepios Hospital Langen, Röntgenstrasse 20, 63225 Langen, Germany. E-mail:

• TEER is a safe and effective treatment for MR and supported by the largest patient experience for any transcatheter intervention. • However, there are potential challenges that suggest alternative therapeutic approaches are needed to address mitral valve complexities: Numerous anatomies potentially unsuitable for TEER.